Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover Conference series)

Pulmonary Circulation

Volumn 4, Issue 2, 2014, Pages 175-184

  Potus, François ^a   Graydon, Colin ^a   Provencher, Steeve ^a   Bonnet, Sébastien ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Angiogenesis; microRNA; Pulmonary arterial hypertension; Skeletal muscle; Vascular remodeling

Indexed keywords

EID: 85026335947     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/675980     Document Type: Review

References (83)

1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119(16):2250-2294. http://www.ncbi.nlm.nih.gov/pubmed/19332472. Accessed August 5, 2013.
2. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries. Chest 2011;139(1):128-137. http://www.ncbi.nlm.nih.gov/pubmed/20558556. Accessed August 13, 2013.
3. Peacock AJ, Murphy NF, McMurray JJV, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30(1):104-109. http://www.ncbi.nlm.nih.gov/pubmed/17360728. Accessed August 5, 2013.
4. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011;8(8):443-455. http://www.ncbi.nlm.nih.gov/pubmed/21691314. Accessed August 5, 2013.
5. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115(5):343-349. http://www.ncbi.nlm.nih.gov/pubmed/1863023. Accessed October 4, 2012.
6. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336(2):111-117. http://www.ncbi.nlm.nih.gov/pubmed/8988890. Accessed August 5, 2013.
7. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 suppl):13S-24S. http://dx.doi.org/10.1016/j.jacc.2004.02.029. Accessed August 5, 2013.
8. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173(9):1023-1030. http://www.ncbi.nlm.nih.gov/pubmed/16456139. Accessed August 5, 2013.
9. Aslam MI, Taylor K, Pringle JH, Jameson JS. MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg 2009;96 (7):702-710. http://www.ncbi.nlm.nih.gov/pubmed/19526617. Accessed August 5, 2013.
10. Suarez Y, Sessa WC. MicroRNAs as novel regulators of angiogenesis. Circ Res 2009;104(4):442-454. http://circres.ahajournals.org/content/104/4/442.abstract. Accessed August 5, 2013.
11. Lee R, Feinbaum R, Ambros V. A short history of a short RNA. Cell 2004;116(2 suppl):S89-S92. http://www.ncbi.nlm.nih.gov/pubmed/15055592. Accessed August 5, 2013.
12. Kwak PB, Iwasaki S, Tomari Y. The microRNA pathway and cancer. Cancer Sci 2010;101(11):2309-2315. http://www.ncbi.nlm.nih.gov/pubmed/20726859. Accessed June 7, 2013.
13. Banerjee J, Chan YC, Sen CK. MicroRNAs in skin and wound healing. Physiol Genomics 2011;43(10):543-556. http://www.pubmedcentral.nih.gov/articlerender.fcgiiartid=3110888&tool=pmcentrez&rendertype=abstract. Accessed August 5, 2013.
14. Donnem T, Fenton CG, Lonvik K, Berg T, Eklo K, Andersen S, Stenvold H, et al. MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS ONE 2012;7(1):e29671.http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3266266&tool=pmcentrez &rendertype=abstract. Accessed August 5, 2013.
15. Gammell P. MicroRNAs: recently discovered key regulators of proliferation and apoptosis in animal cells: identification of miRNAs regulating growth and survival. Cyto-technology 2007;53(1 3):55-63. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2267611&tool=pmcentrez&rendertype=abstract. Accessed August 5, 2013.
16. Paulin R, Courboulin A, Meloche J, Mainguy V, de la Roque ED, Saksouk N, Cote J, Provencher S, Sussman MA, Bonnet S. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 2011;123 (11):1205-1215. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3545712&tool=pmcentrez&rendertype=abstract. Accessed August 1, 2013.
17. Chang Y-M, Kung H-J, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 2007;9(2):90-100. http:// www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1813931&tool=pmcentrez&rendertype=abstract. Accessed August 11, 2013.
18. Johnston PA, Grandis JR. STAT3 signaling: anticancer strategies and challenges. Mol Interventions 2011;11(1):18-26. http://www.pubmedcentral.nih.gov/articlerender.fcgiiartid =3063716&tool=pmcentrez&rendertype=abstract. Accessed August 11, 2013.
19. Lim CP, Fu X-Y. Multiple roles of STAT3 in cardiovascular inflammatory responses. Prog Mol Biol Transl Sci 2012; 106:63-73. http://www.ncbi.nlm.nih.gov/pubmed/22340714. Accessed August 11, 2013.
20. Darnell JE Jr. STATs and gene regulation. Science 1997; 277(5332):1630-1635. http://www.ncbi.nlm.nih.gov/pubmed /9287210. Accessed August 1, 2013.
21. Banes-Berceli AKL, Ketsawatsomkron P, Ogbi S, Patel B, Pollock DM, Marrero MB. Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. Am J Physiol Heart Circ Physiol 2007;293(2): H1291-H1299. http://www.ncbi.nlm.nih.gov/pubmed/17526654. Accessed August 1, 2013.
22. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3(1):46-54. http://www.ncbi.nlm.nih.gov/pubmed/12509766. Accessed August 1, 2013.
23. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L, Michelakis ED. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115(6):1479-1491.http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1136986& tool=pmcentrez&rendertype=abstract. Accessed August 1, 2013.
24. Courboulin A, Tremblay VL, Barrier M, Meloche J, Jacob MH, Chapolard M, Bisserier M, et al. Krüppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res 2011;12:128. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3193170&tool=pmcentrez&rendertype=abstract. Accessed August 1, 2013.
25. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster17/92 pathway. Circ Res 2009;104(10):1184-1191. http://www.ncbi.nlm.nih.gov/pubmed/19390056. Accessed August 1, 2013.
26. Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, Lauzon-Joset J-F, et al. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. J Am Heart Assoc 2013;2(1): e005157. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3603259&tool=pmcentrez&rendertype=abstract. Accessed August 1, 2013.
27. Wong WKP, Knowles JA, Morse JH. Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2005;33(5):438-446. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2715351&tool=pmcentrez&rendertype=abstract. Accessed November 20, 2013.
28. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, Thistlethwaite PA, Kriett JM, Yung G, Rubin LJ, Yuan JX. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003;285(3):L740-L754. http://www.ncbi.nlm.nih.gov/pubmed/12740218. Accessed August 1, 2013.
29. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 2007;104(27):11418-11423. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1903339&tool=pmcentrez&rendertype=abstract. Accessed August 1, 2013.
30. Bonnet S, Paulin R, Sutendra G, Dromparis P, Roy M, Watson KO, Nagendran J, Haromy A, Dyck JR, Michelakis ED. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-ß/NFATaxis. Circulation 2009;120(13):1231-1240. http://www.ncbi.nlm.nih.gov/pubmed/19752325. Accessed August 1, 2013.
31. Courboulin A, Barrier M, Perreault T, Bonnet P, Tremblay VL, Paulin R, Tremblay E, et al. Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J 2012;40(3):618-629. http://www.ncbi.nlm.nih.gov/pubmed/22496325. Accessed August 1, 2013.
32. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beau-lieu C, Thompson R, Lee CT, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11(1):37-51. http://www.ncbi.nlm.nih.gov/pubmed/17222789. Accessed August 1, 2013.
33. Remillard CV, Yuan JX. Activation of K+ channels: an essential pathway in programmed cell death. Am J Physiol Lung Cell Mol Physiol 2004;286(1):L49-L67.
34. Platoshyn O, Golovina VA, Bailey CL, Limsuwan A, Krick S, Juhaszova M, Seiden JE, Rubin LJ, Yuan JX. Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am J Physiol Cell Physiol 2000; 279(5):C1540-C1549. http://www.ncbi.nlm.nih.gov/pubmed/11029301. Accessed August 1, 2013.
35. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 2005;5(6):472-484. http://www.ncbi.nlm.nih.gov/pubmed/15928679. Accessed August 1, 2013.
36. Niu G, Briggs J, Deng J, Ma Y, Lee H, Kortylewski M, Kujawski M, et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1α RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res 2008;6(7):1099-1105. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2775817&tool=pmcentrez&rendertype=abstract. Accessed August 1, 2013.
37. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE. HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005;24(19):3110-3120. http://www.ncbi.nlm.nih.gov/pubmed/15735682. Accessed August 5, 2013.
38. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thebaud B, Bonnet S, Haromy A, et al. An abnormal mitochondrial-hypoxia inducible factor-1α-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006;113 (22):2630-2641. http://circ.ahajournals.org/cgi/content/abstract/113/22/2630. Accessed March 29, 2012.
39. Semenza GL. Hypoxia-inducible factor 1: oxygen homeosta-sis and disease pathophysiology. Trends Mol Med 2001;7 (8):345-350. http://www.ncbi.nlm.nih.gov/pubmed/11516994. Accessed August 1, 2013.
40. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001;276(46):43407-43412. http://www.ncbi.nlm.nih.gov/pubmed/11557773. Accessed August 1, 2013.
41. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3(3):177-185. http://www.ncbi.nlm.nih.gov/pubmed/16517405. Accessed August 1, 2013.
42. Lambert CM, Roy M, Robitaille GA, Richard DE, Bonnet S. HIF-1 inhibition decreases systemic vascular remodelling diseases by promoting apoptosis through a hexokinase 2-dependent mechanism. Cardiovasc Res 2010;88(1):196-204. http://www.ncbi.nlm.nih.gov/pubmed/20498255. Accessed August 1, 2013.
43. Zamzami N, Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol 2001;2 (1):67-71. http://www.ncbi.nlm.nih.gov/pubmed/11413468. Accessed August 1, 2013.
44. McMurtry MS, Bonnet S, Wu X, Dyck JRB, Haromy A, Hashimoto K, Michelakis ED. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 2004;95(8): 830-840. http://circres.ahajournals.org/content/95/8/830.full. Accessed August 1, 2013.
45. Archer SL, Souil E, Dinh-Xuan AT, Schremmer B, Mercier JC, El Yaagoubi A, Nguyen-Huu L, Reeve HL, Hampl V. Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest 1998;101(11):2319-2330. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=508821&tool=pmcentrez&rendertype=abstract. Accessed August 1, 2013.
46. Li S, Ran Y, Zhang D, Chen J, Li S, Zhu D. MicroRNA-138 plays a role in hypoxic pulmonary vascular remodelling by targeting Mst1. Biochem J 2013;452(2):281-291. http://www.ncbi.nlm.nih.gov/pubmed/23485012. Accessed August 12, 2013.
47. Caruso P, Dempsie Y, Stevens HC, McDonald RA, Long L, Lu R, White K, et al. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ Res 2012;111(3):290-300. http://www.ncbi.nlm.nih.gov/pubmed/22715469. Accessed August 12, 2013.
48. Courboulin A, Paulin R, Giguere NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011;208(3): 535-548. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3058572&tool=pmcentrez&rendertype=abstract. Accessed March 24, 2012.
49. Bockmeyer CL, Maegel L, Janciauskiene S, Rische J, Lehmann U, Maus UA, Nickel, N, et al. Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. J Heart Lung Transplant 2012;31(7)764-772. http://dx.doi.org/10.1016/j.healun.2012.03.010. Accessed April 29, 2012.
50. Parikh VN, Jin RC, Rabello S, Gulbahce N, White K, Hale A, Cottrill KA, et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 2012;125(12): 1520-1532. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3353408&tool=pmcentrez&rendertype=abstract. Accessed August 11, 2013.
51. Lee C, Mitsialis SA, Aslam M, Vitali SH, Vergadi E, Kon-stantinou G, Sdrimas K, Fernandez-Gonzalez A, Kourem-banas S. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 2012;126(22):2601-2611. http://www.ncbi.nlm.nih.gov/pubmed/23114789. Accessed August 10, 2013.
52. Li G, Luna C, Qiu J, Epstein DL, Gonzalez P. Role of miR-204 in the regulation of apoptosis, endoplasmic reticulum stress response, and inflammation in human trabecular mesh-work cells. Invest Ophthalmol Vis Sci 2011;52(6):2999-3007. http://www.pubmedcentral.nih.gov/articlerender.fcgiiartid=3109013&tool=pmcentrez&rendertype=abstract. Accessed August 5, 2013.
53. Wang FE, Zhang C, Maminishkis A, Dong L, Zhi C, Li R, Zhao J, et al. MicroRNA-204/211 alters epithelial physiology. FASEB J 2010;24(5):1552-1571. http://www.fasebj.org/content/24/5/1552.full. Accessed August 5, 2013.
54. Lee Y, Yang X, Huang Y, Fan H, Zhang Q, Wu Y, Li J, et al. Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol 2010;6(4):e1000730. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2848541&tool=pmcentrez&rendertype=abstract. Accessed April 21, 2012.
55. Joshi SR, McLendon JM, Comer BS, Gerthoffer WT. MicroRNAs-control of essential genes: implications for pulmonary vascular disease. Pulm Circ 2011;1(3):357-364. http://www.pubmedcentral.nih.gov/articlerender.fcgiiartid=3224427&tool=pmcentrez&rendertype=abstract. Accessed October 29, 2012.
56. Margaillan G, Courboulin A, Potus F, Courchesne A, Couture C, Bonnet P, Provencher S, Bonnet S. RUNX2 regulates the normoxic activation of the hypoxic inducible factor (HIF-1) under the influence of miR-204 in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013;187: A2094. http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A2094. Accessed July 30, 2013.
57. Lee SH, Che X, Jeong J-H, Choi JY, Lee YJ, Lee YH, Bae SC, Lee YM. Runx2 stabilizes hypoxia-inducible factor-1α through competition with pVHL and stimulates angiogene-sis in growth plate hypertrophic chondrocytes. J Biol Chem 2012;287(18):14760-14771. http://www.ncbi.nlm.nih.gov/pubmed/22351759. Accessed March 13, 2012.
58. Kwon T-G, Zhao X, Yang Q, Li Y, Ge C, Zhao G, Franceschi RT. Physical and functional interactions between Runx2 and HIF-1α induce vascular endothelial growth factor gene expression. J Cell Biochem 2011;112(12):3582-3593. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3202060&tool=pmcentrez&rendertype=abstract. Accessed July 30, 2013.
59. von Gise A, Archer SL, MacLean MR, Hansmann G. Full conference report: the first Keystone Symposia Conference on pulmonary vascular disease and right ventricular dysfunction: current concepts and future therapies. Pulm Circ 2013;3(2):275-277.
60. Avellino R, Carrella S, Pirozzi M, Risolino M, Salierno FG, Franco P, Stoppelli P, Verde P, Banfi S, Conte I. miR-204 targeting of Ankrd13A controls both mesenchymal neural crest and lens cell migration. PLoS ONE 2013;8(4):e61099.http://dx.plos.org/10.1371/journal.pone.0061099. Accessed August 5, 2013
61. Cui R-R, Li S-J, Liu L-J, Yi L, Liang QH, Zhu X, Liu GY, et al. MicroRNA-204 regulates vascular smooth muscle cell calcification in vitro and in vivo. Cardiovasc Res 2012; 96 (2):320-329. http://www.ncbi.nlm.nih.gov/pubmed/22871591. Accessed August 12, 2013.
62. Paulin R, Courboulin A, Barrier M, Bonnet S. From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension. J Mol Med (Berl) 2011;89(11):1089-1101. http://www.ncbi.nlm.nih.gov/pubmed/21761156. Accessed March 24, 2012.
63. Courboulin A, Barrier M. Abstract 18277: role of the miR-204/miR-145 communication in the etiology of pulmonary arterial hypertension. Circulation 2011;124(21 suppl.):A18277. http://circ.ahajournals.org/cgi/content/meeting_abstract/124/21_MeetingAbstracts/A18277.
64. Danielsen PH, Møller P, Jensen KA, Sharma AK, Wallin H, Bossi R, Autrup H, et al. Oxidative stress, DNA damage, and inflammation induced by ambient air and wood smoke par-ticulate matter in human A549 and THP-1 cell lines. Chem Res Toxicol 2011;24(2):168-184. http://www.ncbi.nlm.nih.gov/pubmed/21235221. Accessed August 5, 2013.
65. Danielsen PH, Loft S, Jacobsen NR, Jensen KA, Autrup H, Ravanat JL, Wallin H, Møller P. Oxidative stress, inflammation, and DNA damage in rats after intratracheal instillation or oral exposure to ambient air and wood smoke particulate matter. Toxicol Sci 2010;118(2):574-585. http://www.ncbi.nlm.nih.gov/pubmed/20864625. Accessed August 5, 2013.
66. Wang Y, Jing L, Zhao X-M, Han J-J, Xia Z-L, Qin S-C, Wu Y-P, Sun X-J. Protective effects of hydrogen-rich saline on monocrotaline-induced pulmonary hypertension in a rat model. Respir Res 2011;12:26. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3065415&tool=pmcentrez&rendertype=abstract. Accessed August 5, 2013.
67. Bowers R, Cool C, Murphy RC, Tuder RM, Hopken MW, Flores SC, Voelkel NF. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004;169(6):764-769. http://www.ncbi.nlm.nih.gov/pubmed/14701708. Accessed August 5, 2013.
68. Federici C, Aldred MA. Elevated levels of DNA damage in patients with pulmonary arterial hypertension measured by cytokinesis-block micronucleus assay. Am J Respir Crit Care Med 2013;187:A5407. http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5407. Accessed August 12, 2013.
69. Li M, Vattulainen S, Myllykangas S, Koskenvuo J, Alastalo T-P. Abstract 16996: Meta-analysis of DNA microarrays reveals dysregulation of DNA repair genes downstream of BMPR2 in pulmonary arterial hypertension. Circulation 2012; 126(21 suppl.):A16996. http://circ.ahajournals.org/cgi/content /meeting_abstract/126/21_MeetingAbstracts/A16996. Accessed August12, 2013.
70. Courboulin A, Meloche J, Potus F, Margaillan G, Pro-vencher S, Bonnet S. Role for DNA repair machinery in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013;187:A1733. http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A1733. Accessed August 5, 2013.
71. Courboulin A, Krietsch J, Coulombe Y, Poirier G, Masson JY, Bonnet S. Abstract 16424: a critical role of poly-ADP ribose polymerase 1 (PARP-1) in human pulmonary arterial hypertension. Circulation 2011;124(21 suppl.):A16424. http://circ.ahajournals.org/cgi/content/meeting_abstract/124 /21_MeetingAbstracts/A16424. Accessed August 5, 2013.
72. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007;35(4):495-516. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2117903&tool=pmcentrez&rendertype=abstract. Accessed July 31, 2013.
73. Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, Graydon C, et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014; 129(7):786-797. http://www.ncbi.nlm.nih.gov/pubmed/24270264. Accessed March 26, 2014.
74. Badesch DB, Champion HC, Sanchez MAG, Hoeper MM, Loyd JE, Manes A, McGoon M, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 suppl.):S55-S66. http://www.ncbi.nlm.nih.gov/pubmed/19555859. Accessed May 24, 2013.
75. de Man FS, Handoko ML, Groepenhoff H, van't Hul AJ, Abbink J, Koppers RJ, Grotjohan HP, et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2009;34(3):669-675. http://www.ncbi.nlm.nih.gov/pubmed/19720810. Accessed May 24, 2013.
76. Potus F, Malenfant S, Breuils-Bonnet S, Margaillant G, Bonnet S, Provencher S. miR-126, angiogenesis and exercise intolerance in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013;187:A5913. http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5913. Accessed August 5, 2013.
77. Potus F, Paulin R, Breuils-Bonnet S, Tremblay E, Couture C, Michelakis ED, Provencher S, Bonnet S. Downregulation of the angiomiR-126 contributes to the failing right ventricle in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013;187:A5926. http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A5926. Accessed August 5, 2013.
78. Fish JE, Santoro MM, Morton SU, Yu S, Yeh R-F, Wythe JD, Bruneau BG, Stainier DYR, Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15(2):272-284. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2604134&tool=pmcentrez&rendertype=abstract. Accessed March 13, 2012.
79. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008;15(2):261-271. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2685763&tool=pmcentrez&rendertype=abstract. Accessed March 6, 2012.
80. Grant JS, White K, Maclean MR, Baker AH. MicroRNAs in pulmonary arterial remodeling. Cell Mol Life Sci 2013;70(23): 4479-4494. http://www.ncbi.nlm.nih.gov/pubmed/23739951. Accessed August 5, 2013.
81. Brenner A, Mirna Therapeutics. A multicenter phase I study of MRX34, microRNA miR-RX34 liposome injectable suspension. Clinical Trials. gov identifier: NCT01829971. http://www.clinicaltrials.gov/ct2/show/NCT01829971?term=phase&rcv_d=14.
82. Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368(18):1685-1694. http://www.nejm.org/doi/full/10.1056/NEJMoa1209026. Accessed July 15, 2013.
83. Meloche J, Paulin R, Provencher S, Bonnet S. Therapeutic potential of micro RNA modulation in pulmonary arterial hypertension. Curr Vasc Pharmacol. http://www.ncbi.nlm.nih.gov/pubmed/23713859. Published May 13, 2013. Accessed August 5, 2013.